← Compound index
COMPOUND RECORD / EDL

EDLПептид EDL

Glu–Asp–Leu (EDL), a defined tripeptide studied in models of kidney-cell aging. Ovagen reports list the same constituent amino acids but do not establish the sequence of the tested product.

Source linked

What the studies found

Animal research · 2015

Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats

Findings for this preparation

Glomerular filtration was 543.9 µL/min with isolated EDL versus 240.8 with cisplatin alone.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.

Design Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.

Important limitations

  • Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured. Each outcome applies to the specific arm and preparation tested.

Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176. · Publication record

Original source or citation ↗

Study results and tables ↗

Animal research · 2019

Kidney polypeptide complex, EDL, AED and AEDG in aged rats

Findings for this preparation

Two-hour urine output was 4.40 mL with isolated EDL versus 3.51 mL in untreated older rats.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences

Study notes · methods, sources and limitations

Participants or model 35 rats aged 20–24 months. Five randomized groups of seven.

Design Randomized animal comparison of four injected preparations and a control, with renal biochemistry and histology.

Important limitations

  • The paper identifies the short peptides by sequence. The kidney complex trade name is unverified for this report. This was an aging model distinct from cisplatin injury.

Advances in Gerontology. 2019;9(1). English translation. · Publication record

Original source or citation ↗

Study results and tables ↗

Lab research · 2015

Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals

Findings for this preparation

Isolated EDL increased proliferation markers and reduced apoptosis markers in rat kidney tissue cultures. The kidney extract had a larger effect.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model Kidney explants from young and old rats

Important limitations

  • Kidney tissue culture is not a cartilage model or a human renal-treatment trial. The stronger extract response illustrates why mixture effects cannot simply be assigned to one peptide.

Bull Exp Biol Med 159(1):124-127. PMID 26033601 · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About EDL

Research background

Glu–Asp–Leu tripeptide studied in renal-cell aging models. It is distinct from AED/Cartalax.

Compound class
Peptide / preparation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

See preparation-specific records; human benefit not established here

Study methods

Source-specific designs and limitations below

Independent replication

Related reports are not automatically independent evidence

Source access

Linked publications; access and review scope shown per record

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2007 · RU2297239C1 · EDL: defined liver-regeneration peptideMolecule · 18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7

Reported findings

The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.

Bilirubin
18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7Table’s blanket unit label is unsuitable for all analytes; no corrected unit invented
ALT
41.7 ± 2.9 after EDL versus 46.2 ± 3.8 conventional care; baseline 54.5 ± 4.9Marked significant versus baseline, not clearly versus conventional care
All reported results, comparisons and limitations →

Molecule. The claims identify H-Glu-Asp-Leu-OH and related liver-regeneration compositions or uses.

The EDL sequence must not be confused with AEDL Bronchogen; commercial Ovagen equivalence has not been established here.

Publication
RU2297239C1 ↗ · 2007-04-20
Earliest priority / filing
2006-05-30 / 2006-05-30
Original applicant / assignee
Общество С Ограниченной Ответственностью "Сиа Пептайдс"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
38036774 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide stimulating regeneration of liver tissue, pharmaceutical composition based on thereof and method for its using

Inventors: Владимир Хацкелевич Хавинсон (RU); Владимир Хацкелевич Хавинсон; Евгений Иосифович Григорьев (RU); Евгений Иосифович Григорьев; Владимир Викторович Малинин (RU); Владимир Викторович Малинин; Галина Анатольевна Рыжак (RU); Галина Анатольевна Рыжак.

RU2297239C1 · EA010156B1 · WO2007139430A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2015

Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats

Glomerular filtration was 543.9 µL/min with isolated EDL versus 240.8 with cisplatin alone.

Study notes and original source
2015Animal / experimentalFull text available

Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.

I. I. Zamorskii, T. S. Shchudrova, N. S. Lin’kova, T. E. Nichik, V. Kh. Khavinson · Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176.

Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.

Results and tables

Reported findings and study design

Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.

Population or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.

Dose, route and schedule

Interventions were intraperitoneal once daily for four days before and three after cisplatin. Kidney complex 300 µg/kg, EDL 3 µg/kg, AED 3 µg/kg, AEDG 7 µg/kg. Cisplatin was a 6 mg/kg intraperitoneal injection 72 hours before sampling.

Protocol source ↗ · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.

Results · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
MeasureResultComparison, timing and statistics
Glomerular filtration rate433.3 kidney complex, 543.9 EDL, 305.1 AED, 469.9 AEDG vs 240.8 µL/min with cisplatin alone
Plasma creatinine67.43 with kidney complex vs 94.91 µmol/L with cisplatin alonep≤0.05
Diuresis over two hours2.62 kidney complex, 3.02 EDL, 1.81 AED, 2.89 AEDG vs 1.50 mL with cisplatin alone
Selected Table 1 values
Selected Table 1 values
OutcomeIntactCisplatinKidney complexEDLAEDAEDG
Filtration, µL/min502.90240.8433.3543.9305.1469.9
Creatinine, µmol/L64.9094.9167.4368.9582.6077.54
Urine over two hours, mL4.121.502.623.021.812.89

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Source reviewed
Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
Study limitations
  • Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured.
  • Each outcome applies to the specific arm and preparation tested.

Reviewed 2026-11-14.

Read the source ↗

Animal research · 2019

Kidney polypeptide complex, EDL, AED and AEDG in aged rats

Two-hour urine output was 4.40 mL with isolated EDL versus 3.51 mL in untreated older rats.

Study notes and original source
2019Animal / experimentalFull text available

Kidney polypeptide complex, EDL, AED and AEDG in aged rats

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences

I. I. Zamorskii, T. S. Shchudrova, V. G. Zeleniuk, N. S. Linkova, T. E. Nichik, V. K. Khavinson · Advances in Gerontology. 2019;9(1). English translation.

Two-hour urine output was 4.25 mL with the kidney complex, 4.40 with EDL and 4.78 with AED versus 3.51 in controls. AEDG lowered filtration to 406.22 versus 516.32 µL/min.

Results and tables

Reported findings and study design

Randomized animal comparison of four injected preparations and a control, with renal biochemistry and histology.

Population or model 35 rats aged 20–24 months. Five randomized groups of seven.

Dose, route and schedule

Ten daily intraperitoneal doses: kidney polypeptide complex at 300 µg/kg, EDL or AED at 3 µg/kg each, or AEDG at 7 µg/kg. A fifth group was the control.

Protocol source ↗ · Original experimental report, English journal translation, methods and Table 1.

Results · Original experimental report, English journal translation, methods and Table 1.
MeasureResultComparison, timing and statistics
Two-hour diuresis4.25 kidney complex, 4.40 EDL, 4.78 AED, 3.94 AEDG vs 3.51 mL in controlsTable 1 marks the first three active arms significant versus control.
Plasma creatinine42.14 with kidney complex vs 57.65 µmol/L in controlsTable 1 marks this difference significant.
Glomerular filtration406.22 with AEDG vs 516.32 µL/min in controlsTable 1 marks the AEDG decrease significant. The kidney complex value of 605.63 was not marked significant.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
35 rats aged 20–24 months. Five randomized groups of seven.
Source reviewed
Original experimental report, English journal translation, methods and Table 1.
Study limitations
  • The paper identifies the short peptides by sequence. The kidney complex trade name is unverified for this report. This was an aging model distinct from cisplatin injury.

Reviewed 2026-11-14.

Read the source ↗

Experiment described in a patent · 2007

EDL: defined liver-regeneration peptide — RU2297239C1

The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.

Bilirubin · 18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7 · Table’s blanket unit label is unsuitable for all analytes; no corrected unit invented · p<0.05 versus conventional care

Study notes and original source
2007Patent / reported experimentsFull text available

EDL: defined liver-regeneration peptide — RU2297239C1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Владимир Хацкелевич Хавинсон (RU), Владимир Хацкелевич Хавинсон, Евгений Иосифович Григорьев (RU), Евгений Иосифович Григорьев, Владимир Викторович Малинин (RU), Владимир Викторович Малинин, Галина Анатольевна Рыжак (RU), Галина Анатольевна Рыжак · RU2297239C1 · patent family 38036774

The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.

Results and tables

Reported patent results

Reported findings

The patent reports greater bilirubin reduction with EDL-containing care and a before/after ALT change.

Example 6 describes 34 chronic-hepatitis patients aged 30–56 assigned to two groups by a method called randomization. Conventional care: 15. EDL arm: 19 by subtraction. Counts for the three dose subgroups and masking are unspecified.

Population or model Example 6 describes 34 chronic-hepatitis patients aged 30–56 assigned to two groups by a method called randomization. Conventional care: 15. EDL arm: 19 by subtraction. Counts for the three dose subgroups and masking are unspecified.

Results · Russian patent Examples 3 and 6, and Tables 1 and 5. Table 1 cross-checked against the 2012 Ventvil paper.
MeasureResultComparison, timing and statistics
Bilirubin18.6 ± 1.4 after EDL versus 22.3 ± 1.1 conventional care; baseline 27.4 ± 1.7Table’s blanket unit label is unsuitable for all analytes; no corrected unit invented · p<0.05 versus conventional care
ALT41.7 ± 2.9 after EDL versus 46.2 ± 3.8 conventional care; baseline 54.5 ± 4.9Marked significant versus baseline, not clearly versus conventional care · p<0.05 versus baseline
AST and triglyceridesAST 39.5 ± 2.3 versus baseline 40.3 ± 3.2. Triglycerides 2.4 ± 0.3 versus 2.3 ± 0.4.The table gives no significance marker for either outcome.
Symptoms in the EDL arm89% reported less weakness with improved appetite and work capacity. 53% reported less pain.Patent narrative. Control symptom frequencies and dose-specific results are unspecified.

The patent prints 5 mg, 10 µg and 1 µg intramuscularly once daily for 10 days in the severe, moderate and remission subgroups, respectively. The related Eurasian filing EA010156B1 describes 10 µg daily for the entire EDL arm and repeats the same outcome table. The actual dose assignments remain unresolved. Animal Table 1 repeats all values later attributed to Ventvil in a journal paper with a different dose and animal count.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
Example 6 describes 34 chronic-hepatitis patients aged 30–56 assigned to two groups by a method called randomization. Conventional care: 15. EDL arm: 19 by subtraction. Counts for the three dose subgroups and masking are unspecified.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The EDL sequence must not be confused with AEDL Bronchogen; commercial Ovagen equivalence has not been established here.
  • The patent prints 5 mg, 10 µg and 1 µg intramuscularly once daily for 10 days in the severe, moderate and remission subgroups, respectively. The related Eurasian filing EA010156B1 describes 10 µg daily for the entire EDL arm and repeats the same outcome table. The actual dose assignments remain unresolved. Animal Table 1 repeats all values later attributed to Ventvil in a journal paper with a different dose and animal count.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2017

Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis

Synthetic EDL reduced several measures of renal injury, including proteinuria and azotemia, and affected oxidative-stress and energy-related measures.

Study notes and original source
2017Animal / experimentalEnglish abstract

Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Synthetic EDL tripeptide

Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VK · Bulletin of experimental biology and medicine. 2017;163:389-393.

Synthetic EDL reduced several measures of renal injury, including proteinuria and azotemia, and affected oxidative-stress and energy-related measures.

Population / setting
Rats with gentamicin-associated or ischemia/reperfusion kidney injury
Source reviewed
PubMed-indexed abstract and bibliographic metadata checked via Europe PMC; full methods not appraised.
Study limitations
  • The experiment used synthetic EDL in rat kidney injury models. Its findings do not establish a clinical effect.

Reviewed 2026-10-07.

Read the source ↗

Lab research · 2014

[Tripeptides slow down aging process in renal cell culture].

In young and aged renal cell cultures, the short peptides AED and EDL increased proliferation and SIRT6 expression while reducing the senescence-associated markers p16, p21 and p53.

Study notes and original source
2014In vitroEnglish abstract

[Tripeptides slow down aging process in renal cell culture].

Preparation-specific research; no equivalence inferred

Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Poliakova VO, Durnova AO, Nichik TE, Kvetnoĭ IM, D'iakonov MM, Iakutseni PP. · Advances in gerontology = Uspekhi gerontologii

In young and aged renal cell cultures, the short peptides AED and EDL increased proliferation and SIRT6 expression while reducing the senescence-associated markers p16, p21 and p53.

Results and tables

Reported findings and study design

Investigators measured renal-cell proliferation and expression of aging-associated markers. They also modeled how the peptides might bind DNA.

Population or model Young and aged renal cell cultures, with a separate computational DNA interaction analysis.

Results · Original paper abstract
MeasureResultComparison, timing and statistics
Renal-cell proliferationIncreased with AED and EDL.
Senescence-associated markersp16, p21 and p53 expression decreased. SIRT6 expression increased.
Modeled DNA interactionsThe simulations favored binding both peptides to the minor groove of a short alternating AT sequence.

The abstract gives neither culture concentrations nor numerical effects. The modeled binding mechanism requires direct experimental confirmation.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
Young and aged renal cell cultures, with a separate computational DNA interaction analysis.
Source reviewed
Original paper abstract
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-11-16.

Read the source ↗

Lab research · 2015

Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals

Isolated EDL increased proliferation markers and reduced apoptosis markers in rat kidney tissue cultures. The kidney extract had a larger effect.

Study notes and original source
2015In vitroEnglish abstract

Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Chalisova NI, Lin'kova NS, Nichik TE, Ryzhak AP, Dudkov AV, Ryzhak GA · Bull Exp Biol Med 159(1):124-127. PMID 26033601

Compared kidney polypeptide complex with T-31/AED and T-35/EDL. The short peptides changed proliferation and apoptosis markers, with smaller effects than the complex.

Population / setting
Kidney explants from young and old rats
Source reviewed
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Study limitations
  • Kidney tissue culture is not a cartilage model or a human renal-treatment trial.
  • The stronger extract response illustrates why mixture effects cannot simply be assigned to one peptide.

Reviewed 2026-09-29.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗